IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia (STOP-VT)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Ventricular Tachycardia | Device: Magnetic irrigated ablation catheter | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases |
- Percentage of Participants Free From VT at 1 Year Post-Treatment [ Time Frame: 1 Year follow-up ]In order to qualify for inclusion in the chronic success statistic, patients must first be an acute success and must have had no VTs identified in their ICD history post ablation therapy.
| Enrollment: | 53 |
| Study Start Date: | June 2009 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Magnetic irrigated ablation catheter
Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
|
Device: Magnetic irrigated ablation catheter
Magnetic irrigated catheter to be used with the magnetic navigation system
Other Names:
|
Detailed Description:
Catheter ablation of ventricular tachycardia (VT) is greatly facilitated by using a substrate mapping approach - that is, mapping of the left ventricle during sinus or paced rhythm to identify diseased myocardium. Using three dimensional electroanatomical mapping, it is possible to reconstruct an anatomical rendering of the left ventricle based on voltage. For hemodynamically stable or unstable VTs, various electrophysiologic maneuvers can then be used to identify the critical portions of the VT circuit within the scar (entrainment mapping, identification of diastolic potentials, identification of electrically-unexcitable scar, fractionated potentials and pace mapping).
These methods are limited by the resolution of the substrate map, accuracy of catheter manipulation, and operator skill. To this end, a magnetic navigation system has been developed that allows for remote cardiac mapping. When used in concert with a compatible electroanatomical mapping system, it is possible to create a high-density ventricular substrate map of healed myocardial infarction. By removing the necessity for technical skill with catheter manipulation, this system has the potential for both improving the efficacy of VT ablation and expanding the clinical use of this substrate mapping approach.
Recently, a higher-powered, irrigated tip catheter has become available in certain markets for use in cardiac arrhythmia ablations. This study will evaluate the outcomes of using this magnetic irrigation ablation catheter during mapping and ablation of VT while also using remote magnetic navigation.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject must be between the ages of 18 - 80 years
- Willing to provide prior written informed consent per local ethics committee guidelines
- Subjects must present with ventricular tachycardia, characterized by: history of myocardial scar and spontaneous ventricular tachycardia
- Able to be safely exposed to static magnetic fields
- No in-situ devices are present or any in-situ devices have been verified to be compatible to magnetic fields
Exclusion Criteria:
- Presence of a mobile ventricular thrombus
- Inability to access the left ventricle
- Subjects must not have any contraindications to short-term anticoagulation
- Subjects must not have a life expectancy of <1 year due to a medical illness
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00851279
| United States, Indiana | |
| Krannert Institute of Cardiology | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Pennsylvania | |
| Hospital of the University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Czech Republic | |
| Na Homolce Hospital | |
| Prague, Czech Republic, 15630 | |
| Germany | |
| Herzzentrum Universitat Leipzig | |
| Leipzig, Germany, 04289 | |
| Principal Investigator: | Petr Neuzil, MD | Na Homolce Hospital, Prague, CZ |
More Information
Additional Information:
| Responsible Party: | Stereotaxis |
| ClinicalTrials.gov Identifier: | NCT00851279 History of Changes |
| Other Study ID Numbers: |
PM-CLIN-013 |
| Study First Received: | February 24, 2009 |
| Results First Received: | December 2, 2013 |
| Last Updated: | July 27, 2015 |
Keywords provided by Stereotaxis:
|
arrhythmia ventricular tachycardia ablation mapping electrophysiology |
Additional relevant MeSH terms:
|
Tachycardia Tachycardia, Ventricular Arrhythmias, Cardiac |
Heart Diseases Cardiovascular Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on July 21, 2017